Potency and safety analysis of hemp-derived delta-9 products: The hemp vs. cannabis demarcation problem

Add links
Legal status
Legal status
  • DE: NpSG (Industrial and scientific use only)
  • UK: Class B
  • N-(1-Amino-3,3-dimethyl-1-oxo-2-butanyl)-1-pentyl-1H-5-bromoindazole-3-carboxamide
PubChem CID
Chemical and physical data
Molar mass423.355 g·mol−1
3D model (JSmol)
  • NC(=O)[C@@H](NC(=O)c1nn(CCCCC)c2ccc(Br)cc21)C(C)(C)C
  • InChI=1S/C19H27BrN4O2/c1-5-6-7-10-24-14-9-8-12(20)11-13(14)15(23-24)18(26)22-16(17(21)25)19(2,3)4/h8-9,11,16H,5-7,10H2,1-4H3,(H2,21,25)(H,22,26)/t16-/m1/s1

ADB-5'Br-PINACA (5'-Br-ADB-PINACA) is an indazole-3-carboxamide based synthetic cannabinoid receptor agonist that has been sold as a designer drug. It was first identified in Abu Dhabi in September 2022,[1] but has subsequently been found in the US and Europe.[2] While formal pharmacology studies have not yet been carried out, ADB-5'Br-PINACA is believed to be a highly potent synthetic cannabinoid with similar potency to compounds such as MDMB-FUBINACA and 5F-ADB which have been responsible for numerous fatal and non-fatal drug overdoses, consistent with previously reported compounds from the patent literature showing bromination of the indazole ring at the 5-, 6- or 7- positions to increase potency over the unsubstituted analogues.[3] ADB-5'Br-PINACA is the 5'-bromo analog of ADB-PINACA.


ADB-5'Br-PINACA can be synthesized from a "half finished" synthesis precursor known as ADB-5-Br-INACA, related to MDMB-5Br-INACA.[4]


ADB-5'Br-PINACA is not specifically scheduled in the United States at the federal level as of October 20, 2023 but may be considered illegal under the federal analogue act if intended for consumption as a structural analog of the Schedule I cannabinoid ADB-PINACA.

See also


  1. ^ "The ADJD's Centre of Forensic and Digital Sciences Discovers a New Synthetic Cannabinoid Substance". Emirates 24/7. 15 May 2023.
  2. ^ "ADB-5'Br-PINACA Monograph". The Center For Forensic Science Research & Education. April 2023.
  3. ^ WO 2009106982, Buchler IP, Hayes MJ, Hedge SG, Hockerman SL, Jones DE, Kortum SW, Rico JG, Tenbrink RE, Wu KK, "Indazole Derivatives", published 3 September 2009, assigned to Pfizer Inc. 
  4. ^ Deventer MH, Persson M, Norman C, Liu H, Connolly MJ, Daéid NN, et al. (October 2023). "In vitro cannabinoid activity profiling of generic ban-evading brominated synthetic cannabinoid receptor agonists and their analogs". Drug Testing and Analysis. doi:10.1002/dta.3592. PMID 37903509. S2CID 264671035.